New Zealand markets open in 6 hours 29 minutes

ICON Public Limited Company (ICLR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
250.23-5.82 (-2.27%)
As of 09:30AM EST. Market open.

ICON Public Limited Company

South County Business Park
Dublin 18
353 1 291 2000

IndustryDiagnostics & Research
Full-time employees37,960

Key executives

NameTitlePayExercisedYear born
Dr. Steven A. CutlerCEO & Director2.21MN/A1960
Mr. Brendan BrennanChief Financial Officer914kN/A1979
Mr. Diarmaid CunninghamChief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec.N/AN/A1975
Jonathan CurtainVP of Corp. Fin. & Investor RelationsN/AN/AN/A
Mr. Thomas N. O'LearyChief Information OfficerN/AN/AN/A
Mr. Simon HolmesExec. VP of Investor Relations & Corp. Devel.N/AN/A1967
Ms. Niamh MurphyDirector of Corp. CommunicationsN/AN/AN/A
Mr. David GreenVP of MarketingN/AN/AN/A
Mr. Joe CroninChief HR OfficerN/AN/AN/A
Ms. Dana Lynn Poff Snr.Exec. VP of Program ManagementN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Corporate governance

ICON Public Limited Company’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.